Business Wire

MIPI Alliance Releases MIPI CCS, a New Specification that Streamlines Integration of Image Sensors in Mobile Devices

Jaa

The MIPI® Alliance, an international organization that develops interface specifications for mobile and mobile-influenced industries, today released a new specification that provides a standardized way to integrate image sensors in mobile-connected devices.

The new specification, MIPI Camera Command Set v1.0 (MIPI CCS v1.0), defines a standard set of functionalities for implementing and controlling image sensors. The specification is offered for use with MIPI Camera Serial Interface 2 v2.0 (MIPI CSI-2 v2.0) and is now available for download. In an effort to help standardize use of MIPI CSI-2, MIPI Alliance membership is not required to access the specification.

MIPI CSI-2 is the industry’s most widely used hardware interface for deploying camera and imaging components in mobile devices. The introduction of MIPI CCS to MIPI CSI-2 further increases interoperability, and reduces integration and costs for complex imaging and vision systems.

“MIPI Alliance is building on its success in the mobile camera and imaging ecosystem with MIPI CCS, a new specification that will enhance the market-enabling conveniences MIPI CSI-2 already provides,” said Joel Huloux, chairman of MIPI Alliance. “The availability of MIPI CCS will help image sensor vendors promote greater adoption of their technologies and it will help developers accelerate time-to-market with innovative designs targeting the mobile industry, connected cars, the Internet of Things, AR/VR and other areas.”

From startups to global organizations, companies are integrating image sensor components into their designs for specialized and mass-market products. To date, image sensor integration has required device-specific software to enable basic operations. As imaging applications have become more sophisticated and manufacturers have begun deploying multiple image sensors in their products, implementation has become more complex and time consuming.

MIPI CCS alleviates these challenges by making it possible to craft a common software driver to configure the basic functionalities of any off-the-shelf image sensor that is compliant with MIPI CCS and MIPI CSI-2 v2.0. The new specification provides a complete command set that can be used to integrate basic image sensor features such as resolution, frame rate and exposure time, as well as advanced features like phase detection auto focus (PDAF), single frame HDR or fast bracketing.

“The overall advantage of MIPI CCS is that it will enable rapid integration of basic camera functionalities in plug-and-play fashion without requiring any device-specific drivers, which has been a significant pain point for developers,” said Mikko Muukki, technical lead for MIPI CCS. “MIPI CCS will also give developers flexibility to customize their implementations for more advanced camera and imaging systems.”

MIPI CCS v1.0 was developed for use with MIPI CSI-2 v2.0 and, as such, is backward compatible with earlier versions of the MIPI CSI-2 interface. It is implemented on either of two physical layers from MIPI Alliance: MIPI C-PHY or MIPI D-PHY.

Join the MIPI CCS v1.0 Webinar

Developers are invited to attend a webinar “Introduction to MIPI Camera Command Set v1.0” on 10 January at 11 a.m. EST, 8 a.m. PST. For information and registration, please go to: http://bit.ly/2jMIp2g.

To discover more about MIPI Alliance and to connect with its social networks, follow its Twitter page, join its LinkedIn group and like its Facebook page. To join MIPI Alliance, use the Join MIPI link on the organization’s site.

About MIPI Alliance

MIPI Alliance (MIPI) develops interface specifications for mobile and mobile-influenced industries. There is at least one MIPI specification in every smartphone manufactured today. Founded in 2003, the organization has 300 member companies worldwide and 13 active working groups delivering specifications within the mobile ecosystem. Members of the organization include handset manufacturers, device OEMs, software providers, semiconductor companies, application processor developers, IP tool providers, test and test equipment companies, as well as camera, tablet and laptop manufacturers. For more information, please visit www.mipi.org.

MIPI® is a registered trademark owned by MIPI Alliance. MIPI CSI-2SM v2.0, MIPI CCS SM, MIPI C-PHYSM and MIPI D-PHYSM are service marks of the MIPI Alliance.

Contact information

Press Contact:
Interprose for MIPI Alliance
Lisa McCausland, +1 303-888-2137
Lisa.mccausland@interprosepr.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Ultra-Low Power Lattice sensAI Leads Mass Market Enablement of Artificial Intelligence in Edge Devices21.5.2018 15:00Tiedote

Lattice Semiconductor Corporation (NASDAQ: LSCC) today unveiled Lattice sensAI™ – a complete technology stack combining modular hardware kits, neural network IP cores, software tools, reference designs and custom design services – to accelerate integration of machine learning inferencing into broad market IoT applications. With solutions optimized for ultra-low power consumption (under 1 mW–1 W), small package size (5.5 mm2 –100 mm2), interface flexibility (MIPI® CSI-2, LVDS, GigE, etc.), and high-volume pricing (~$1-$10 USD), Lattice sensAI stack fast-tracks implementation of edge computing close to the source of data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005011/en/ (Graphic: Business Wire) “Lattice sensAI addresses the unmet need for flexible, low cost, ultra-low power AI silicon solutions suited for rapid deployment across a wide range of emerging, mass market IoT applications,” said Deepak Boppana, senior

NioCorp Awards Contract to Rockwell Automation on Groundbreaking Critical Minerals, Mining and Processing Facility in Nebraska21.5.2018 15:00Tiedote

NioCorp Developments Ltd. (TSX: NB, OTCQX: NIOBF), a developer of superalloy metals, has awarded a major contract to Rockwell Automation (NYSE: ROK) to engineer, design and procure process automation and instrumentation for NioCorp’s proposed critical minerals, mining and processing facility in Elk Creek, Nebraska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005228/en/ Three superalloy metals – niobium, scandium and titanium – are expected to be produced by the facility as early as 2021. These critical materials are used in the aerospace, defense, automotive, clean energy, commercial aviation and mega-infrastructure sectors. Generally, these superalloys enable increased strength and lighter weight in transportation and other systems, leading to better fuel efficiency and lower greenhouse gas and other air emissions, according to NioCorp. “We selected Rockwell Automation and its partners to automate our process equip

Biosimilars could facilitate early access to life changing biological treatments for patients says Celltrion Healthcare21.5.2018 14:27Tiedote

At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Celltrion Healthcare today advocated for healthcare systems to introduce biologics earlier in a patient’s treatment regimen in order to improve clinical outcomes. Several studies show that the early introduction of biologics can bring greater clinical benefit to patients.1,2,3,4,5,6 However, only a limited number of patients have access to biological treatment due to the high-cost of biologics and current reimbursement policies determined by pharmacoeconomic evaluations. Since the introduction of biosimilars, the overall cost of biological treatments has reduced in Europe, allowing an increased number of patients to access this important treatment option earlier in their course of treatment.7 Professor Jørgen Jahnsen said, “For the treatment of inflammatory bowel disease, biological treatments are proven to be the most efficacious medical therapy and their ea

Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 14:00Tiedote

Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba

ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV21.5.2018 13:11Tiedote

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1 Juluca is a 2-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide,2 and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson).1 Deborah Waterhouse, CEO ViiV Healthcare said, “The European Commission Decision for Juluca is very positive news for people living with

Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-121.5.2018 13:06Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA® (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences Ireland UC]).1 ViiV Healthcare, as the marketing authorisation holder, will market dolutegravir/rilpivirine in all countries in the European Union and European Economic Area. Dolutegravir/rilpivirine is the first two-drug regimen, once-daily, single-pill for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor (INI).1 “The European Commission Decision for dolutegravir/rilpivirine marks a significant milestone in our 25-year commitment to make HIV history,” said Brian Woo

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme